Phase II SBIR Award Kickoff Meeting

Fairbanks team members: Laboratory Technician Alexa Lopez, CEO Alan Schneyer, COO Elissa Brown, Consultant Dr. Melissa Brown and Consultant Lara Bonomi

With a Phase II SBIR award in hand, Fairbanks Pharmaceuticals CEO Alan Schneyer and team are moving quickly to execute the project plan and achieve the goals of the grant. At a kickoff meeting at the Baystate Research Facility in Springfield, MA, Fairbanks team members worked on planning activities and enjoyed a celebratory lunch that was joined by their scientific and technical colleagues working in the BRF.

The SBIR grant, entitled “Development Of Novel Diabetes Therapies Based On Neutralizing FSTL3 Activity”, provides a total of $1.8M in funding for two years of research. The immediate focus of this research is to test the lead compound in animal models of diabetes for safety and effectiveness. The remaining goals are to identify the mechanism(s) involved in its beneficial effects and engineering the compound to be a more effective therapeutic in humans.

Fairbanks Pharmaceuticals SBIR Phase 2 grant
Fairbanks Co-Founders Elissa Brown and Alan Schneyer celebrate the Phase II SBIR Award